Back to top
more

STERIS (STE)

(Delayed Data from NYSE)

$225.18 USD

225.18
487,798

+3.33 (1.50%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

STERIS' (STE) Q4 Earnings Surpass Estimates, Margins Rise

STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.

Steris (STE) Q4 Earnings and Revenues Surpass Estimates

Steris (STE) delivered earnings and revenue surprises of 4.46% and 4.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products' Earnings Roster for May 13: SDC, STE & More

Many medical product companies register strong earnings growth in Q1, riding on huge market adoption of their COVID-19-related support products and growing demand for non-elective procedures.

Steris (STE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Steris (STE) Earnings Expected to Grow: Should You Buy?

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Add STERIS (STE) Stock in Your Portfolio

Investors continue to be optimistic about STERIS (STE) on its strong segmental growth in the third quarter of 2020.

Nalak Das headshot

5 Top S&P 500 Stocks That Rallied Last Week Defying Coronavirus

Despite coronovirus upsurge, a handful of S&P 500 stocks rallied last week. Some of them carry a favorable Zacks Rank with strong potential for future growth.

Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down

The coronavirus outbreak had an immaterial impact on Walgreens Boots' (WBA) second-quarter fiscal 2020 results.

Bruker (BRKR) Q4 Earnings Miss Estimates, Revenues Beat

Bruker's (BRKR) fourth-quarter 2019 results reflect strong performances by the majority of its segments and geographies.

STERIS' (STE) Organic Growth Robust Amid Bottom-Line Hurdles

STERIS (STE) continues to register stellar organic growth across all four operating segments.

    Neogen (NEOG) Q3 Earnings & Revenues Miss, Margins Decline

    Neogen's (NEOG) fiscal third-quarter 2020 results reflect strength in the Animal Safety segment.

    Zacks.com featured highlights include: Medtronic, STERIS and Enova International

    Zacks.com featured highlights include: Medtronic, STERIS and Enova International

    Tirthankar Chakraborty headshot

    3 Top Stocks to Buy for Earnings Acceleration

    Studies have shown that a majority of stocks had seen acceleration in earnings before a rally in stock price.

    Steris (STE) Down 6.9% Since Last Earnings Report: Can It Rebound?

    Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    National Vision (EYE) Rides on Robust Growth Across All Lines

    National Vision (EYE) continues to register strong segmental performances.

    Here's Why You Should Add STERIS (STE) Stock in Your Portfolio

    Investors continue to be optimistic about STERIS (STE) on its strong segmental performance in Q3.

    STERIS (STE) Stock Hits New 52-Week High: What's Driving it?

    STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with several tuck-in acquisitions.

    STERIS' (STE) Growth Picture Impressive Amid Rising Costs

    STERIS (STE) growing steadily on favorable underlying market trends, along with new product and service offerings.

    Insulet (PODD) Q4 Earnings Lag Estimates, Revenues Beat

    Insulet's (PODD) fourth-quarter 2019 results reflect strong segmental performances.

    Intersect ENT (XENT) Reports Narrower-Than-Expected Q4 Loss

    Intersect ENT (XENT) exhibits a dismal performance in the fourth quarter of 2019.

    Tandem Diabetes (TNDM) Q4 Earnings Beat Estimates, Margins Up

    Tandem Diabetes (TNDM) once again registers strong domestic pump shipment in Q4.

    Teleflex (TFX) Earnings and Revenues Beat Estimates in Q4

    Teleflex's (TFX) fourth-quarter 2019 results reflect strong segmental performances.

    Integra (IART) Q4 Earnings Surpass Estimates, Margins Up

    Integra's (IART) fourth-quarter 2019 results reflect strong segmental performances.

    Globus Medical (GMED) Lags Q4 Earnings, Beats on Revenues

    Globus Medical (GMED) registers impressive growth within U.S. Spine on record recruiting of competitive representatives in Q4.

    NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q4

    NuVasive's (NUVA) Biologics business returns to growth in the fourth quarter of 2019.